Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 981-991

  MacKenna, Deidre A ^a   Montag, Annika ^a   Boyer, Serge H ^a   Linemeyer, David L ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

Chemotherapy; Cytarabine; Hepatocellular carcinoma; Liver targeting; Nucleosides; P450 CYP3A4; Prodrug

Indexed keywords

CYTARABINE; CYTOCHROME P450 3A; FLUDARABINE PHOSPHATE; MB 07133; MB 07191; NUCLEOSIDE TRIPHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTARABINE; CYTOCHROME P-450 CYP3A; DRUG DELIVERY SYSTEMS; INFUSIONS, INTRAVENOUS; LIVER; LIVER NEOPLASMS; MALE; MICE; NUCLEOSIDES; PRODRUGS; THYMIDINE; TISSUE DISTRIBUTION; VIDARABINE;

EID: 69049085538     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0953-5     Document Type: Article

References (43)

1. GK Abou-Alfa L Schwartz S Ricci D Amadori A Santoro A Figer J De Greve JY Douillard C Lathia B Schwartz I Taylor M Moscovici LB Saltz 2006 Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 4293 4300
2. VI Avramis W Plunkett 1982 Metabolism and therapeutic efficacy of 9-beta-d-arabinofuranosyl-2-fluoroadenine against murine leukemia P388 Cancer Res 42 2587 2591
3. AS Befeler AM Di Bisceglie 2002 Hepatocellular carcinoma: diagnosis and treatment Gastroenterology 122 1609 1619
4. AS Befeler PH Hayashi AM Di Bisceglie 2005 Liver transplantation for hepatocellular carcinoma Gastroenterology 128 1752 1764
5. V Biro DM Goldenberg 1971 Hematological toxicity of 1-beta-d- arabinofyranosylcytosine, and its prevention by deoxycytidine, in the mouse Chemotherapy 16 29 43
6. SH Boyer Z Sun H Jiang J Esterbrook JE Gomez-Galeno W Craigo KR Reddy BG Ugarkar DA MacKenna MD Erion 2006 Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-d-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma J Med Chem 49 7711 7720
7. J Braess S Voss G Jahns-Streubel C Schoch T Haferlach W Kern S Keye E Schleyer W Hiddemann 2000 The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity Br J Haematol 110 170 179
8. GW Camiener CG Smith 1965 Studies of the enzymatic distribution of cytosie arabinoside-I. Enzyme distribution and species specificity Biochem Pharmacol 14 1405 1416
9. S Chaube W Kreis K Uchida ML Murphy 1968 The teratogenic effect of 1-β-d-arabinofuranosylcytosine in the rat: protection by deoxycytidine Biochem Pharmacol 17 1213 1216
10. L Danhauser W Plunkett M Keating F Cabanillas 1986 9-beta-d- arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma Cancer Chemother Pharmacol 18 145 152
11. JP Durham DH Ives 1969 Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-d-arabinofuranosylcytosine phosphorylation Mol Pharmacol 5 358 375
12. M El Mouelhi MS Didolkar EG Elias FP Guengerich FC Kauffman 1987 Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver Cancer Res 47 460 466
13. MD Erion KR Reddy SH Boyer MC Matelich J Gomez-Galeno RH Lemus BG Ugarkar TJ Colby J Schanzer PD Van Poelje 2004 Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver J Am Chem Soc 126 5154 5163
14. MD Erion PD van Poelje DA Mackenna TJ Colby AC Montag JM Fujitaki DL Linemeyer DA Bullough 2005 Liver-targeted drug delivery using HepDirect prodrugs J Pharmacol Exp Ther 312 554 560
15. V Gandhi W Plunkett 2002 Cellular and clinical pharmacology of fludarabine Clin Pharmacokinet 41 93 103
16. V Gandhi E Estey M Du MJ Keating W Plunkett 1997 Minimum dose of fludarabine for the maximal modulation of 1-beta-d-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy Clin Cancer Res 3 1539 1545
17. C Garrett D Santi 1979 A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts Anal Biochem 99 268 273
18. B Grasl-Kraupp B Rutttkay-Nedecky L Mullauer H Taper W Huber W Brusch R Schulte-Herman 1997 Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression Hepatology 25 906 912
19. I Graziadei T Kelly M Schirmer FH Geisen W Vogel G Konwalinka 1998 Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′, 2′-difluorodeoxycytidine on human hepatoma HepG2 cells J Hepatol 28 504 509
20. SD Harrison Jr JA Burdeshaw RG Crosby AM Cusic EP Denine 1978 Hematology and clinical chemistry reference values for C57BL/6 X DBA/2 F1 mice Cancer Res 38 2636 2639
21. WH Harvey TR Fleming G Beltran JH Saiers N Oishi DD Von Hoff 1987 Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group study Cancer Treat Rep 71 1111 1112
22. MB Herrera S Bruno S Buttiglieri C Tetta S Gatti MC Deregibus B Bussolati G Camussi 2006 Isolation and characterization of a stem cell population from adult human liver Stem Cells 24 2840 2850
23. Imagawa D, Ma B, Venook AP, Bissell M, Peterson C, Erion MD, NIculae I, Jensen J, Bullough D, Foyt HL (2007) A Phase I/II study to assess the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) infusion of MB07133 in subjects with unresectable hepatocellular carcinoma (HCC). In: AACR. American Association for Cancer Research Annual Meeting Proceedings, Los Angeles, CA. Abstract# 2649
24. GP Jamieson MB Snook JS Wiley 1990 Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells Leuk Res 14 475 479
25. L Liu Y Cao C Chen X Zhang A McNabola D Wilkie S Wilhelm M Lynch C Carter 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 11851 11858
26. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul J-L, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J (2007) Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). ASCO. J Clin Oncol Abstract# 4587
27. Montag A, Steward K, Rolzin P, Linemeyer DL, Erion MD (2004) The effect of dexamethasone treatment on CYP3A and activity distribution, the liver targeting of MB07133 and CYP3A activity in a highly proliferating state in rats. Hepatology 40: Abstract #649A
28. D Motola-Kuba D Zamora-Valdes M Uribe N Mendez-Sanchez 2006 Hepatocellular carcinoma. An overview Ann Hepatol 5 16 24
29. GI Murray PJ Paterson RJ Weaver SWB Ewen WT Melvin MD Burke 1993 The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma Cancer 71 36 43
30. KK Ng JN Vauthey TM Pawlik GY Lauwers JM Regimbeau J Belghiti I Ikai Y Yamaoka SA Curley DM Nagorney IO Ng ST Fan RT Poon 2005 Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database Ann Surg Oncol 12 364 373
31. T Ogiso M Tatematsu S Tamano R Hasegawa N Ito 1990 Correlation between medium-term liver bioassay system data and results of long-term testing in rats Carcinogenesis 11 561 566
32. CR Padgham CC Boyle XJ Wang SM Raleigh MC Wright AJ Paine 1993 Alteration of transcription factor mRNAs during the isolation and culture of rat hepatocytes suggests the activation of a proliferative mode underlies their de-differentiation Biochem Biophys Res Commun 197 599 605
33. MG Pallavicini 1984 Cytosine arabinoside: molecular, pharmacokinetic and cytokinetic considerations Pharmacol Ther 25 207 238
34. W Plunkett V Hug MJ Keating S Chubb 1980 Quantitation of 1 - d-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1 - d- arabinofuranosylcytosine therapy Cancer Res 40 588 591
35. C Rodriguez-Antona MT Donato A Boobis RJ Edwards PS Watts JV Castell MJ Gomez-Lechon 2002 Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells Xenobiotica 32 505 520
36. T Roskams 2006 Liver stem cells and their implication in hepatocellular and cholangiocarcinoma Oncogene 25 3818 3822
37. LA Shipley TJ Brown JD Cornpropst M Hamilton WD Daniels HW Culp 1992 Metabolism and disposition of gemcitabine, an oncolytic deoxycitidine analog, in mice, rats and dogs Drug Metab Dispos 20 849 855
38. Suto T, Miyazawa J, Watanabe Y, Suto K, Yoshida Y, Sakata Y (1997) The effect of YNK-01 (an oral prodrug of cytarabine) on hepatocellular carcinoma. Semin Oncol 24(S6):122-129
39. SS Thorgeirsson VM Factor EG Snyderwine 2000 Transgenic mouse models in carcinogenesis research and testing Toxicol Lett 112-113 553 555
40. SC Tobias RF Borch 2004 Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug Mol Pharm 1 112 116
41. AP Venook 2004 Key research issues in the management of hepatocellular carcinoma Cancer Chemother Pharmacol 54 Suppl 1 S87 S90
42. E Weber P Bannasch 1994 Dose and time dependence of the cellular phenotype in rat hepatic preneoplasia and neoplasia induced by continuous oral exposure to N-nitrosomorpholine Carcinogenesis 15 1235 1242
43. YJ Zhang S Chen WY Tsai H Ahsan RM Lunn LY Wang CJ Chen RM Santella 2000 Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B1 and 4-aminobiphenyl DNA adducts Biomarkers 5 295 306